What Treatments Are Used for Chronic Uveitis?
At a Glance
When steroid eye drops fail to control chronic anterior uveitis or cause serious side effects, doctors prescribe systemic immunomodulatory therapies. These include oral immunosuppressants like methotrexate or targeted biologic injections like adalimumab to calm the immune system and protect vision.
In this answer
5 sections
Yes, if your anterior uveitis flares become chronic, recurrent, or stubborn, there are effective treatments beyond steroid eye drops. When topical steroids are no longer sufficient to control inflammation or begin to cause side effects, doctors transition to systemic immunomodulatory therapies—medications that work throughout your body to calm your immune system. These corticosteroid-sparing options include conventional oral immunosuppressants and targeted biologic injections, which can help break the cycle of drops and prevent long-term eye damage [1][2].
The Limits of Steroid Eye Drops
Steroid eye drops are typically the first line of defense against an anterior uveitis flare. However, when the inflammation becomes chronic, relying on these drops long-term carries significant risks. Prolonged use of topical steroids can lead to steroid toxicity, which includes serious complications like the development of cataracts (clouding of the eye’s lens) and glaucoma (high eye pressure that can damage the optic nerve) [3][4].
When you require long-term topical steroids or when the inflammation remains active despite their use, it is a clinical indicator that your treatment plan needs to be escalated [3][5]. Transitioning to systemic therapies is designed to achieve a corticosteroid-sparing effect—meaning they control the inflammation effectively so you can safely reduce or stop using steroids [6][1]. Early initiation of these systemic therapies is strongly encouraged to prevent progressive vision impairment and the need for surgical interventions [2][7].
Intermediate Steps: Steroid Injections
Before moving completely to systemic medications, your doctor might suggest a localized approach. Periocular injections (steroid shots placed around or near the eye) can serve as an intermediate step. These can provide a stronger dose of medication directly to the area, which might be preferred if the chronic inflammation is limited to just one eye [8]. However, for bilateral (both eyes) or highly recurrent cases, early systemic management is often prioritized [8].
Conventional Immunosuppressants
The first step in moving beyond eye drops often involves conventional systemic immunosuppressants. These are medications taken by mouth that broadly reduce the activity of the immune system to stop it from attacking the eye.
Commonly used medications in this category include:
- Antimetabolites: Drugs like methotrexate, mycophenolate mofetil, and azathioprine [1][9].
- Calcineurin inhibitors: Drugs such as cyclosporine [1].
These conventional therapies are foundational in the stepwise approach to managing chronic anterior uveitis [10][11]. Because they suppress the immune system, they require routine laboratory monitoring—including regular blood tests to check complete blood counts, liver function, and kidney function—to detect and prevent any potential toxicity [12][13]. Day-to-day, these medications can sometimes cause side effects like mild gastrointestinal upset or fatigue. For specific medications like methotrexate, doctors often prescribe a folic acid supplement to help minimize side effects like mouth sores or hair thinning.
It is also important to know that these medications do not work overnight. They often take weeks or even one to three months to build up in your system and take full effect. During this waiting period, your doctor may prescribe a “bridge therapy”—such as a temporary, short course of oral steroids—to keep the inflammation under control. While taking any steroids can be concerning when you are trying to avoid steroid toxicity, a brief course of oral steroids is used temporarily to calm the eye quickly. It carries different, usually manageable, short-term side effects (like temporary insomnia or mild weight gain) compared to the specific long-term, irreversible eye damage (like cataracts and glaucoma) caused by chronic eye drops.
Biologic Therapies
When conventional immunosuppressants are ineffective, or in specific cases where a faster or more targeted approach is needed, doctors may recommend biologics. Biologics are advanced medications that target specific proteins in the immune system responsible for inflammation, rather than suppressing the entire immune system.
The most widely used biologic agents for non-infectious uveitis are Tumor necrosis factor-α (TNF-α) inhibitors. These medications are given in one of two ways:
- Subcutaneous injection: Medications like adalimumab can be self-administered at home using a simple auto-injector pen [14][15].
- Intravenous infusion: Medications like infliximab require visiting a clinic or hospital infusion center to receive the medication through an IV [14][15].
Research has shown that biologic therapies can be more effective than conventional oral medications in achieving control of uveitis [16], and they are particularly effective at reducing the need for systemic or topical corticosteroids [17][18]. In some specific populations, such as children with juvenile idiopathic arthritis (JIA) who develop uveitis, biologics like adalimumab are often used early in the treatment process, sometimes right after topical drops or methotrexate fail [7][19]. If TNF-α inhibitors do not work, newer targeted therapies called JAK inhibitors (such as baricitinib) are emerging as alternative options [20].
Safety Considerations for Biologics
While biologics generally have a favorable safety profile and are highly effective, they do carry specific safety considerations. Because they alter the immune response, they can increase the risk of infections [21][22]. Before starting a biologic therapy, your doctor will require screening for latent (hidden) infections, such as tuberculosis and hepatitis, to ensure the medication is safe for you [23][24].
Before Making the Transition
Before stepping up to systemic immunosuppressants or biologics, your medical team must confirm the root cause of your chronic flares. It is critical to differentiate between non-infectious autoimmune uveitis (which responds to immune-suppressing drugs) and uveitis caused by an infection, such as the cytomegalovirus (CMV) or herpes simplex virus (HSV) [25][26]. If the uveitis is infectious, suppressing the immune system could worsen the condition, and specific antiviral therapies are required instead [27][28].
Common questions in this guide
Why do doctors stop using steroid eye drops for chronic uveitis?
What is a corticosteroid-sparing treatment?
How do conventional immunosuppressants treat uveitis?
What are biologic therapies for uveitis?
Why must infections be ruled out before starting systemic uveitis therapies?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific signs or side effects indicate it's time for me to transition from steroid eye drops to a systemic medication?
- 2.Are my current flares considered non-infectious, and what tests have we done to rule out infectious causes before starting immune therapies?
- 3.Between conventional immunosuppressants like methotrexate and biologics like adalimumab, which approach do you recommend for my specific situation and why?
- 4.What routine monitoring or blood tests will I need if I start a systemic therapy?
- 5.If I need a bridge therapy while waiting for the new medication to work, what is our specific timeline for safely tapering off my steroids?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (28)
- 1
The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management.
Foster CS, Kothari S, Anesi SD, et al.
Survey of ophthalmology 2016; (61(1)):1-17.
PMID: 26164736 - 2
Recurrent and chronic anterior uveitis: Long-term outcome and treatment strategies.
Sharon Y, Goren L, Barayev E, et al.
Indian journal of ophthalmology 2024; (72(Suppl 2)):S248-S253 doi:10.4103/IJO.IJO_1042_23.
PMID: 38146973 - 3
Dr. Gottlieb et al reply.
Gottlieb C, Berard RA, Levy DM, Fortin E
The Journal of rheumatology 2023; doi:10.3899/jrheum.2023-0509.
PMID: 37399460 - 4
Impact of complications in adult anterior uveitis in a Finnish single-centre registry study.
Leino A, Siiskonen M, Ohtonen P, Hautala NM
BMJ open ophthalmology 2025; (10(1)) doi:10.1136/bmjophth-2025-002210.
PMID: 41327639 - 5
ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.
Quartier P, Baptiste A, Despert V, et al.
Annals of the rheumatic diseases 2018; (77(7)):1003-1011 doi:10.1136/annrheumdis-2017-212089.
PMID: 29275333 - 6
Paediatric anterior uveitis management in the USA: a single-centre, 10-year retrospective chart review exploring the efficacy and safety of systemic immunomodulatory therapy.
Huynh E, Elhusseiny AM, Nihalani BR
Eye (London, England) 2023; (37(7)):1325-1330 doi:10.1038/s41433-022-02121-3.
PMID: 35650322 - 7
Pediatric Uveitis: Impact of Anti-Tumor Necrosis Factor-Alpha on Ocular Complications.
Sharon Y, Karchever K, Goren L, et al.
Ocular immunology and inflammation 2025; (33(6)):905-912 doi:10.1080/09273948.2025.2465776.
PMID: 39931957 - 8
Ultrawide-field fluorescein angiography features in patients with anterior uveitis.
Nguyen NV, Oyeniran E, Zeleny A, et al.
Eye (London, England) 2024; (38(9)):1742-1747 doi:10.1038/s41433-024-03012-5.
PMID: 38472380 - 9
[Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel].
Diwo E, Sève P, Trad S, et al.
La Revue de medecine interne 2018; (39(9)):687-698 doi:10.1016/j.revmed.2018.03.001.
PMID: 29610003 - 10
The Steroid-Sparing Effect of Adalimumab in the Treatment for the Recurrent Phase of Vogt-Koyanagi-Harada Disease.
Shinagawa M, Namba K, Mizuuchi K, et al.
Ocular immunology and inflammation 2023; (31(3)):501-505 doi:10.1080/09273948.2022.2037657.
PMID: 35212595 - 11
The Efficacy and Safety of Adalimumab in Treating Pediatric Noninfectious Chronic Anterior Uveitis With Peripheral Retinal Vascular Leakage: A Pilot Study.
Song H, Zhao C, Xiao J, et al.
Frontiers in medicine 2022; (9()):813696 doi:10.3389/fmed.2022.813696.
PMID: 35425781 - 12
Pharmacotherapy for non-infectious uveitis: spotlight on phase III clinical trials of locally injected or implanted therapeutics and systemic immunomodulatory drugs.
Shields MK, Ferreira LB, Ali SB, et al.
Journal of ophthalmic inflammation and infection 2025; (15(1)):49 doi:10.1186/s12348-025-00502-9.
PMID: 40473986 - 13
Management of JIA associated uveitis.
Maccora I, Simonini G, Guly CM, Ramanan AV
Best practice & research. Clinical rheumatology 2024; (38(3)):101979 doi:10.1016/j.berh.2024.101979.
PMID: 39048481 - 14
Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors.
Bessone F, Björnsson ES
The Medical clinics of North America 2023; (107(3)):623-640 doi:10.1016/j.mcna.2022.12.008.
PMID: 37001957 - 15
Biological Agent Switching in Patients With Juvenile Idiopathic Arthritis: A Tertiary Center Experience.
Güngörer V, Çelikel E, Ekici Tekin Z, et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2023; (29(6)):255-261 doi:10.1097/RHU.0000000000001974.
PMID: 37068267 - 16
Noninfectious Uveitis in Rheumatology: Patterns, Treatment, and Outcomes.
Younus R, Saeed MA, Arshad M, et al.
Cureus 2023; (15(6)):e39965 doi:10.7759/cureus.39965.
PMID: 37416043 - 17
Perspectives for immunotherapy in noninfectious immune mediated uveitis.
Touhami S, Gueudry J, Leclercq M, et al.
Expert review of clinical immunology 2021; (17(9)):977-989 doi:10.1080/1744666X.2021.1956313.
PMID: 34264142 - 18
Expert opinion on the use of biological therapy in non-infectious uveitis.
Touhami S, Diwo E, Sève P, et al.
Expert opinion on biological therapy 2019; (19(5)):477-490 doi:10.1080/14712598.2019.1595578.
PMID: 30888881 - 19
Recommendations for the management of childhood juvenile idiopathic arthritis-type chronic anterior uveitis.
Smith JR, Matthews JM, Conrad D, et al.
Clinical & experimental ophthalmology 2021; (49(1)):38-45 doi:10.1111/ceo.13856.
PMID: 33426782 - 20
Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.
Thomas J, Kuthyar S, Shantha JG, et al.
Annals of eye science 2021; (6()) doi:10.21037/aes-2019-dmu-10.
PMID: 34131629 - 21
Biologic therapies for psoriasis and eyes.
Burek-Michalska A, Turno-Kręcicka A, Grant-Kels JM, Grzybowski A
Clinics in dermatology 2023; (41(4)):523-527 doi:10.1016/j.clindermatol.2023.08.003.
PMID: 37586569 - 22
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations.
Nielsen OH, Hammerhøj A, Ainsworth MA, et al.
Drugs 2025; (85(1)):67-85 doi:10.1007/s40265-024-02115-3.
PMID: 39532820 - 23
[Application of TNF-alpha inhibitors in treatment of uveitis associated with ankylosing spondylitis].
Razumova IY, Godzenko AA
Vestnik oftalmologii 2018; (134(5. Vyp. 2)):257-262 doi:10.17116/oftalma2018134051257.
PMID: 30499526 - 24
Recent advances in the treatment of juvenile idiopathic arthritis-associated uveitis.
Chen JL, Abiri P, Tsui E
Therapeutic advances in ophthalmology 2021; (13()):2515841420984572 doi:10.1177/2515841420984572.
PMID: 33681703 - 25
[Differential diagnosis of anterior uveitis].
Thurau S, Pleyer U
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2016; (113(10)):879-892 doi:10.1007/s00347-016-0328-3.
PMID: 27578315 - 26
Antiviral Therapy for Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV)-Induced Anterior Uveitis: A Systematic Review and Meta-Analysis.
Testi I, Aggarwal K, Jaiswal N, et al.
Frontiers in medicine 2021; (8()):686427 doi:10.3389/fmed.2021.686427.
PMID: 34277661 - 27
Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus, and Cytomegalovirus.
Terada Y, Kaburaki T, Takase H, et al.
American journal of ophthalmology 2021; (227()):191-200 doi:10.1016/j.ajo.2021.03.020.
PMID: 33773985 - 28
Differential Diagnosis of Viral-Induced Anterior Uveitis.
Relvas LJ, Caspers L, Chee SP, et al.
Ocular immunology and inflammation 2018; (26(5)):726-731 doi:10.1080/09273948.2018.1468470.
PMID: 29869892
This page provides educational information about systemic treatments for chronic anterior uveitis. Always consult your ophthalmologist or rheumatologist before making decisions about your medication regimen.
Get notified when new evidence is published on Anterior uveitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.